ES2565345T3 - Nuevos inhibidores de la reductasa de s-nitrosoglutatión - Google Patents

Nuevos inhibidores de la reductasa de s-nitrosoglutatión Download PDF

Info

Publication number
ES2565345T3
ES2565345T3 ES11742796.3T ES11742796T ES2565345T3 ES 2565345 T3 ES2565345 T3 ES 2565345T3 ES 11742796 T ES11742796 T ES 11742796T ES 2565345 T3 ES2565345 T3 ES 2565345T3
Authority
ES
Spain
Prior art keywords
group
formula
new
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11742796.3T
Other languages
English (en)
Inventor
Xicheng Sun
Jian Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nivalis Therapeutics Inc
Original Assignee
Nivalis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nivalis Therapeutics Inc filed Critical Nivalis Therapeutics Inc
Application granted granted Critical
Publication of ES2565345T3 publication Critical patent/ES2565345T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El compuesto de formula (I)**Fórmula** o una sal farmaceuticamente aceptable del mismo, en la que X se selecciona de entre el grupo que consiste en O y S; Y se selecciona de entre el grupo que consiste en O y S; Z se selecciona de entre el grupo que consiste en Z1, Z2, Z3 y Z4, en donde Z1 es**Fórmula** Z2 es**Fórmula** Z3 es**Fórmula** y Z4 es**Fórmula** con la condicion de que Z unicamente es Z4 cuando al menos uno de X o Y es S; R1 se selecciona de entre el grupo que consiste en hidrogeno, alquilo (C1-C6), cicloalquilo (C3-C7), haloalquilo (C1-C6), arilalquilo (C1-C4) no sustituido, arilalquilo (C1-C6) sustituido, heteroalquilo (C1-C6), arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido; R2 se selecciona de entre el grupo que consiste en hidrogeno, halogeno, ciano y alcoxi (C1-C6); R3 se selecciona de entre el grupo que consiste en hidrogeno, halogeno, alquilo (C1-C6), haloalquilo (C1-C6), alcoxi (C1-C6), ciano y N,N-dimetilamino; R4 se selecciona de entre el grupo que consiste en tetrazol, oxadiazolona, tiadiazolona, metilsulfonilcarbamoilo y N-hidroxicarbamoilo; y R5 se selecciona de entre el grupo que consiste en carboxi, tetrazol, oxadiazolona, tiadiazolona, metilsulfonilcarbamoilo y N-hidroxicarbamoilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
5
15
25
35
45
55
65
antibacterianos tales como alcohol bencílico o metilparabenos; (3) antioxidantes tales como ácido ascórbico o bisulfito de sodio; (4) agentes quelantes tales como ácido etilendiaminotetraacético; (5) tampones tales como acetatos, citratos o fosfatos; y (5) agentes para el ajuste de la tonicidad tales como cloruro de sodio o dextrosa. El pH puede ajustarse con ácidos o con bases, tales como ácido clorhídrico o hidróxido de sodio. Una preparación parenteral puede estar contenida en ampollas, en jeringas desechables o en viales de dosis múltiples hechos de vidrio o de plástico.
Las composiciones farmacéuticas adecuadas para su uso inyectable pueden comprender soluciones o dispersiones acuosas estériles (cuando sean solubles en agua) y polvos estériles para la preparación extemporánea de soluciones o de dispersiones inyectables estériles. Para la administración intravenosa, algunos vehículos adecuados incluyen solución salina fisiológica, agua bacteriostática, Cremophor EL (BASF, Parsippany, N.J.), o solución salina tamponada con fosfato (PBS). En todos los casos, la composición debe ser estéril y debe ser fluida hasta el punto de que exista una fácil jeringabilidad. La composición farmacéutica debe ser estable en las condiciones de elaboración y de almacenamiento, y debe preservarse frente a la acción contaminante de microorganismos tales como bacterias y hongos.
El vehículo puede ser un disolvente o un medio de dispersión que comprende, por ejemplo, agua, etanol, un poliol (por ejemplo, glicerol, propilenglicol y polietilenglicol líquido y similares) y mezclas adecuadas de los mismos. La fluidez apropiada puede mantenerse, por ejemplo, mediante el uso de un recubrimiento tal como lecitina, mediante el mantenimiento del tamaño de partícula requerido en el caso de una dispersión, y mediante el uso de tensioactivos. La prevención de la acción de los microorganismos puede conseguirse mediante diversos agentes antibacterianos y antifúngicos, por ejemplo, parabenos, clorobutanol, fenol, ácido ascórbico, timerosal y similares. En muchos casos será preferible incluir en la composición agentes isotónicos, por ejemplo, azúcares, polialcoholes tales como manitol
o sorbitol, y sales inorgánicas tales como cloruro de sodio. La absorción prolongada de las composiciones inyectables puede conseguirse mediante la inclusión en la composición de un agente que retarde la absorción, por ejemplo, monoestearato de aluminio y gelatina.
Las soluciones inyectables estériles pueden ser preparadas mediante la incorporación del reactivo activo en la cantidad requerida en un disolvente apropiado con uno o una combinación de los ingredientes enumerados anteriormente, según se requiera, seguido de una esterilización por filtración. Generalmente, las dispersiones se preparan mediante la incorporación de al menos un compuesto de la invención en un vehículo estéril que contiene un medio de dispersión básico y cualquier otro ingrediente requerido. En el caso de los polvos estériles para la preparación de soluciones inyectables estériles, algunos métodos a modo de ejemplo de preparación incluyen secado a vacío y liofilización, produciendo ambos un polvo de un compuesto de la invención más cualquier ingrediente adicional deseado a partir de una solución previamente filtrada estéril de los mismos.
Las composiciones orales incluyen generalmente un diluyente inerte o un vehículo comestible. Pueden estar incluidas, por ejemplo, en cápsulas de gelatina, o comprimidas en comprimidos. Con el fin de una administración terapéutica oral, el compuesto de la invención puede ser incorporado con excipientes y usado en forma de comprimidos, de tabletas o de cápsulas. Las composiciones orales también pueden prepararse mediante el uso de un vehículo fluido para su uso como un enjuague bucal, en el que el compuesto del vehículo fluido se aplica por vía oral y se enjuaga y se expectora o se ingiere. Como parte de la composición pueden incluirse agentes ligantes y/o materiales adyuvantes farmacéuticamente compatibles.
Para una administración mediante inhalación, los compuestos son administrados en forma de un nebulizador de aerosol desde un recipiente presurizado o un dispensador que contiene un propulsor adecuado, por ejemplo, un gas tal como dióxido de carbono, un líquido nebulizado o un polvo seco desde un dispositivo adecuado. Para una administración transmucosal o transdérmica, en la formulación se usan unos penetrantes apropiados para la barrera que va ser atravesada. Dichos penetrantes son conocidos generalmente en la técnica, e incluyen, por ejemplo, para una administración transmucosal, detergentes, sales biliares y derivados del ácido fusídico. La administración transmucosal puede llevarse a cabo mediante el uso de aerosoles nasales o de supositorios. Para la administración transdérmica, los reactivos activos se formulan en ungüentos, bálsamos, geles o cremas, como se sabe de forma general en la técnica. Los reactivos también pueden prepararse en forma de supositorios (por ejemplo, con bases para supositorios convencionales tales como manteca de cacao y otros glicéridos) o enemas de retención para su administración rectal.
En una forma de realización, los compuestos de la invención se preparan con vehículos que los protegerán frente una rápida eliminación desde el cuerpo. Por ejemplo, puede usarse una formulación de liberación controlada, incluyendo implantes y sistemas de administración microencapsulados. Pueden usarse polímeros biodegradables biocompatibles, tales como etilenacetato de vinilo, polianhídridos, ácido poliglicólico, colágeno, poliortoésteres y ácido poliláctico. Los métodos para la preparación de dichas formulaciones serán evidentes para los expertos en la técnica.
También pueden usarse suspensiones liposómicas (incluyendo liposomas dirigidos a las células infectadas con anticuerpos monoclonales contra los antígenos víricos) como vehículos farmacéuticamente aceptables. Éstos pueden prepararse de acuerdo con los métodos conocidos por los expertos en la técnica, por ejemplo, según se
14
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES11742796.3T 2010-02-12 2011-02-10 Nuevos inhibidores de la reductasa de s-nitrosoglutatión Active ES2565345T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30395210P 2010-02-12 2010-02-12
US303952P 2010-02-12
PCT/US2011/024353 WO2011100433A1 (en) 2010-02-12 2011-02-10 Novel s-nitrosoglutathione reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2565345T3 true ES2565345T3 (es) 2016-04-04

Family

ID=44368117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11742796.3T Active ES2565345T3 (es) 2010-02-12 2011-02-10 Nuevos inhibidores de la reductasa de s-nitrosoglutatión

Country Status (20)

Country Link
US (3) US8759548B2 (es)
EP (1) EP2533638B1 (es)
JP (2) JP5878484B2 (es)
KR (1) KR20120138746A (es)
CN (1) CN102869255B (es)
AU (1) AU2011215833B2 (es)
BR (1) BR112012019529A2 (es)
CA (1) CA2787633A1 (es)
DK (1) DK2533638T3 (es)
ES (1) ES2565345T3 (es)
HR (1) HRP20160450T1 (es)
HU (1) HUE029012T2 (es)
IL (1) IL220956A (es)
PL (1) PL2533638T3 (es)
RS (1) RS54618B1 (es)
RU (1) RU2585763C2 (es)
SI (1) SI2533638T1 (es)
SM (1) SMT201600135B (es)
WO (1) WO2011100433A1 (es)
ZA (1) ZA201205374B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100433A1 (en) * 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Novel s-nitrosoglutathione reductase inhibitors
JP5639665B2 (ja) 2010-02-12 2014-12-10 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのクロモン阻害剤
PT2624695E (pt) 2010-10-08 2015-12-01 Nivalis Therapeutics Inc Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
US8785643B2 (en) 2010-12-16 2014-07-22 N30 Pharmaceuticals, Inc. Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
WO2012170371A1 (en) * 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2021040814A1 (en) * 2019-08-23 2021-03-04 NOTA Laboratories, LLC Nitric oxide generating systems for nasal inhalation
CN117088862B (zh) * 2023-08-22 2025-09-12 南华大学 一种硫代色元酮衍生物和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
EP0888369A1 (en) 1996-02-21 1999-01-07 Glycomed Incorporated Sialyl lewis x mimetics containing flavanoid backbones
ES2233998T3 (es) * 1996-03-05 2005-06-16 Sterix Limited Compuestos que comprenden un grupo sulfamato.
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
KR20000001793A (ko) * 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
WO2001080855A1 (en) 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US7049308B2 (en) 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US20030181510A1 (en) 2002-03-19 2003-09-25 Robert Baker Inhibition of muscle regeneration following myectomy
KR20060011785A (ko) 2002-06-27 2006-02-03 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. Ａｌｄｈ 억제에 유용한 화합물
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US8138165B2 (en) 2002-10-22 2012-03-20 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
JP2007525952A (ja) 2003-06-04 2007-09-13 デューク・ユニバーシティ Ｓ−ニトロソグルタチオンレダクターゼを調節するための組成物および方法
CN1241921C (zh) 2003-07-09 2006-02-15 东华大学 含氟异黄酮衍生物、制造方法及其用途
JP5036532B2 (ja) 2004-04-08 2012-09-26 アルメテオン、インコーポレイテッド 血液凝固疾患治療のための物質およびその方法
CN1950353B (zh) 2004-04-08 2011-06-01 ARYx医疗有限公司 治疗凝血紊乱的药物和方法
MX2007007480A (es) * 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de cromano y su uso como ligandos del receptor 5-ht.
WO2006099193A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP2046769A2 (en) * 2006-07-27 2009-04-15 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
EP2084141A4 (en) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
EP2581451B1 (en) * 2007-12-13 2016-03-09 Indiana University Research and Technology Corporation Compounds for inhibiting mammalian s-nitrosoglutathione reductase
WO2010107476A1 (en) 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
WO2011100433A1 (en) * 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Novel s-nitrosoglutathione reductase inhibitors
JP5639665B2 (ja) 2010-02-12 2014-12-10 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのクロモン阻害剤
WO2012170371A1 (en) * 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors

Also Published As

Publication number Publication date
US20160045478A1 (en) 2016-02-18
AU2011215833B2 (en) 2015-07-09
DK2533638T3 (en) 2016-04-25
SMT201600135B (it) 2016-07-01
IL220956A (en) 2015-09-24
CN102869255A (zh) 2013-01-09
KR20120138746A (ko) 2012-12-26
RS54618B1 (sr) 2016-08-31
JP2013519680A (ja) 2013-05-30
ZA201205374B (en) 2013-09-25
BR112012019529A2 (pt) 2019-09-24
US20120289555A1 (en) 2012-11-15
EP2533638A1 (en) 2012-12-19
US9707212B2 (en) 2017-07-18
US20140275185A1 (en) 2014-09-18
AU2011215833A1 (en) 2012-08-30
SI2533638T1 (sl) 2016-05-31
HK1178742A1 (zh) 2013-09-19
US8759548B2 (en) 2014-06-24
HUE029012T2 (en) 2017-02-28
RU2012132692A (ru) 2014-02-10
EP2533638B1 (en) 2016-02-10
US9187447B2 (en) 2015-11-17
JP2016040285A (ja) 2016-03-24
CA2787633A1 (en) 2011-08-18
RU2585763C2 (ru) 2016-06-10
HRP20160450T1 (hr) 2016-05-20
EP2533638A4 (en) 2013-06-05
PL2533638T3 (pl) 2016-08-31
WO2011100433A1 (en) 2011-08-18
JP5878484B2 (ja) 2016-03-08
CN102869255B (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
ES2565345T3 (es) Nuevos inhibidores de la reductasa de s-nitrosoglutatión
CA3154618A1 (en) Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN104640540B (zh) 与抗炎活性偶联的增强的抗流感剂
ES2542728T3 (es) Composiciones farmacéuticas que tienen la biodisponibilidad deseable
ES2610425T3 (es) Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico
US9402913B2 (en) Cyclosporine A steroid conjugates
ES2691805T3 (es) Medicamento para el tratamiento de una enfermedad ocular
US9636376B2 (en) Stable compositions of peptide epoxy ketones
ES2966093T3 (es) Formulación farmacéutica que contiene un derivado de quinolona
CA3238758A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
TW202200121A (zh) 治療方法
ES2326471T3 (es) Composicion de uso topico que comprende un ciclofructano, un vehiculo y un farmaco.
AU2021201251B2 (en) Antimicrobial compounds, compositions, and uses thereof
ES3037855T3 (en) One step milling process for preparing micronized paliperidone esters
KR20200039029A (ko) 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
US20250275918A1 (en) Lipid compositions and methods for nucleic acid delivery
ES2600469T3 (es) Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
KR20100045513A (ko) 감염의 치료 또는 제어를 위한, 퀴놀론을 포함하는 조성물 및 방법
ES2693122T3 (es) Composición
JP6509811B2 (ja) ジブチルヒドロキシトルエンの安定化方法
ES2618374T3 (es) Composiciones y métodos para mejorar la absorción de glucosa
US20230102999A1 (en) Deuterated niclosamide
WO2004096279A1 (ja) 注射用組成物
KR102475176B1 (ko) 정맥내 항바이러스 치료
ES2864735T3 (es) Formulaciones oftálmicas que contienen gamma-lactamas sustituidas y métodos para el uso de las mismas